Systemic Procaterol (Meptin) as a CONTROLLER for Asthma

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

UTHSCSA Pediatric Resident Curriculum for the PICU ASTHMA IN THE PICU.
Use of Medications in Asthma Cyril Grum, M.D. Department of Internal Medicine *Based on the University of Michigan Guidelines for Clinic Care and the National.
Cases from Aug 2014 Cases from Aug 2014 Ryan Padrez & Patrick Peebles 9/10/14.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 32 Bronchodilator Drugs and the Treatment of Asthma.
ASTHMA Presented by your School Nurse.
1 Copyright © 2012, 2008, 2002, 1998, 1994, 1989, 1984, 1978 by Mosby, Inc., an affiliate of Elsevier Inc. Reminder:  QUIZ NEXT WEEK ON:  Anti-infectives,
นส. นุชนาถ ตั้งเวนิช เจริญสุข รหัส A chronic inflammatory disorder of the airway Airway hyperresponsiveness Recurrent episodes of wheezing,
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy.
Asthma What is Asthma ? V1.0 1997 Merck & ..
Drugs For Treating Asthma
BRONCHIAL ASTHMA YOUSEF ABDULLAH AL TURKI MBBS,DPHC,ABFM
BRONCHIAL ASTHMA DR.K.PREETHI. RESPIRATORY SYSTEM TRACHEA TRACHEA PAIR OF BRONCHI PAIR OF BRONCHI BRONCHIOLES BRONCHIOLES.
Ibrahim Tawhari. Prepared by:. Scernario:  Khalid 14 years old come to the clinic c/o shortness of breath for one day duration.  He is a known asthmatic.
22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 76 Drugs for Asthma.
Asthma Management Pathophysiology and Management University of Utah Center for Emergency Programs and The Utah Asthma Program.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Department faculty and hospital therapy of medical faculty and department internal diseases of medical prophylactic faculty. BRONCHIAL ASTHMA.
Classification and guideline treatment
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
DRUGS USED IN ASTHMA. Asthma is an inflammatory disease of the airways characterized by episodes of acute bronchoconstriction causing shortness of breath,
Case No. 12 SH, 25 years old with a history of asthma since childhood presented to the OPD clinic with complaints of worsening dyspnea and wheezing. He.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
SGA 2003-W SS Slide 1 Capacity of Oral SINGULAIR to Prevent Asthma Exacerbations CApacidad de SIngulair ™ Oral en la Prevencion de Exacerbaciones.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
Dr Dhaher Jameel Salih Al-habbo FRCP London UK Assistant Professor Department of Medicine.College of Mdicine University of Mosul.
ASTHMA UPDATE Chad Fowler, M.D. 10/27/04. Asthma: Why do we care? It’s common: Affects million persons in U.S. Most common chronic disease of childhood:
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Drugs Used to Treat Asthma Dr. Najlaa Saadi Ismael Department of Pharmacology Mosul college of Medicine University of Mosul.
Prof.Dr. Muhi K. Aljanabi MRCPCH; DCH; FICMS Consultant Pediatric Pulmonologist.
ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.
β2 Agonists Albuterol and other inhaled short-acting selective β2 agonists are indicated for treatment of intermittent episodes of bronchospasm and are.
Asthma 1 د. ميريانا البيضة. DIAGNOSIS 2 3 Definition of asthma.
Dr Mazen Qusaibaty MD, DIS / Head Pulmonary and Internist Department Ibnalnafisse Hospital Ministry of Syrian health – Dr Mazen.
Asthma ( Part 1 ) Dr.kassim.M.sultan F.R.C.P. Objectives: 1-Define asthma 2-Identify its aggravating factors 3-Describe its clinical features 4-Illustrate.
Department of Pharmacology
Asthma Review of Pathophysiology and Treatment. n definition of asthma –Asthma is a chronic inflammatory disorder of the airways in which many cells &
Diagnosis of asthma in adolescents and adults D.Anan Esmail Seminar Training Primary Care Asthma+ COPD
Respiratory System Disorders
Asthma HESS 509 CHAPTER SEVENTEEN
Pharmacology of Anti- Asthmatic Medications
Eileen G. Holland, Pharm.D., BCPS Associate Professor
A New Anti-inflammatory Therapy For COPD
Respiratory disorders
Immunology Unit Department of Pathology King Saud University
Research where it is most needed National Respiratory Strategy
Chapter 9 Respiratory Drugs.
BRONCHIAL ASTHMA YOUSEF ABDULLAH AL TURKI MBBS,DPHC,ABFM
Drugs affecting the respiratory system
Bronchial Asthma Dr.Radhakrishna. S. A. Bronchial Asthma Dr.Radhakrishna. S. A.
Medications for the respiratory system
Disorders of the respiratory system
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Systemic Procaterol (Meptin) as a CONTROLLER for Asthma
Bronchial Asthma.
Disorders of the Respiratory System
Asthma in Athletes Taken From:
The Modern Management of Asthma: Getting it right Part 2
RESPIRATORY DISORDERS ( ASTHMA )
Nonsteroidal antiasthma agents
Respiratory disorders
Evidence-Based Asthma Guidelines
By: Moshe Jerasi 6th Hour
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Drugs Affecting the Respiratory System
Chronic Obstructive Pulmonary Disease
Drugs used in asthma.
Immunology Unit Department of Pathology King Saud University
ASTHMA Dr. Saviour K. Assoah (Medicine Dept). OUTLINE Definition Epidemiology Risks / precipitating factors Symptoms and signs Pathophysiology Types of.
Presentation transcript:

Systemic Procaterol (Meptin) as a CONTROLLER for Asthma PART 1 Good day to you doctor. Today I would like to discuss with you Procaterol (Meptin) as a controller medication for your patients with Asthma. I will be focusing on the Systemic Forms of Meptin, particularly the Tablet Format: 25mcg and 50mcg tablets.

INFLAMMATION Environmental Risk Factors Definition of Asthma Environmental Risk Factors Airway Hyperresponsiveness Airway Limitation Symptoms Triggers INFLAMMATION As you know well, doctors, asthma is defined as a chronic inflammatory disorder of the airways, characterized by inflammation, airway hyperresponsiveness, and reversible airway obstruction. In susceptible individuals, the inflammation leads to an increase in airway responsiveness to various stimuli, and causes recurrent symptoms associated with airway obstruction that is often reversible either spontaneously or with treatment. Global Strategy for Asthma Management and Prevention, 1995

Common Asthma Triggers Allergens 1 Respiratory Tract Infections Irritants (Dust, Strong Odor, etc.) Temperature Change Emotion / Stress Exercise / Physical Activity 2 3 4 5 6 The most common stimuli or asthma triggers are listed here in this slide. As an exposure of asthmatic subjects to the stimuli induces asthmatic episodes, identification and control or avoidance of these stimuli are far most important in the management of asthma, which can reduce manifestation of symptoms and may decrease airway inflammation and hyperresponsiveness in a long-term.

Philippine Consensus Report on the Diagnosis & Management of Asthma Step 2: Mild, Persistent Controller: Daily medication: - Inhaled Corticosteroids 200-500 up to 800 mcg/day or Cromolyn Sodium Alternative Controller: -Long-Acting b2 Agonist or Sustained Release Theophylline None Step 1: Mild, Intermittent Reliever: - Inhaled Short-Acting b2 Agonist as needed, not > 3x/week Alternative Reliever: - Short-Acting Oral bronchodilator (b2 Agonist or Theophyllime) - Inhaled Short-Acting b2 Agonist as needed, not > 3-4x/day Step 4: Severe, Persistent - Add Ipratropium Bromide - Inhaled Corticosteroids 800-2,000 mcg/day - Long-Acting Bronchodilator (Inhaled or Oral b2 Agonist, Sustained Release Theophylline) - Oral Long-Acting b2 Agonist + Theophylline - Oral Steroid > 7.5 mg/day, daily or alternate day Step 3: Moderate, Persistent - Add Long-Acting Bronchodilator - Low Dose Oral Steroid < 7.5 mg/day, daily or alternate day As discussed earlier, the underlying condition of asthma is inflammation. It is, therefore, important to address the inflammation in the management of asthma. In order to address these problems, the Philippine Consensus Report in the Diagnosis & Management of Asthma recommends the use of controllers, which are mainly steroids and anti-inflammatory agents as the first choice. However, once you are faced with any of the situations wherein you do not want to increase dosage of the controller given to your patients, the condition of your patients is not properly controlled by the controller given, or you do not want to use steroids even in a form of inhaler, like for your pediatric cases, the consensus recommends to use any of the oral or long-acting bronchodilators as an additional controller.

Treatment Modality for Asthma Steroids Anti-inflammatory drugs Oral/Long acting bronchodilators Anti-inflammatory effects Reduce airway hyperreactivity Sustained bronchodilation Inflammation Airway Hyperreactivity Controller Bronchoconstriction Asthmatic attack Reliever Knowing that the underlying conditions of asthma are inflammation and airway hyperresponsiveness, I hope you will agree with us that bronchodilators having the following features are more recommended as an additional controller to steroids or anti-inflammatory drugs; 1. Anti-inflammatory effect, 2. Reduces airway hyperresponsiveness, and 3. Sustained bronchodilating action. Inhaled Bronchodilators Rapid onset of action Potent bronchodilation

Site of Action of Anti-asthmatic Drugs GTP cGMP GMP Anti-cholinergic Agents Inhibition Guanylate Cyclase Bronchoconstriction Phosphodiesterase Adenylate Cyclase Bronchodilation Xanthine Derivatives b2 Stimulants Activation Inhibition ATP cAMP AMP As you know well, we have three bronchodilators available in the market now, which are beta 2 stimulants or agonists, xanthine derivatives, and anti-cholinergic agents. Our product, Procaterol, Meptin belongs to the beta 2 stimulant category. Release Inhibition Bronchoconstriction Mucous edema Mast cell Histamine, LTs Inhibition Inhibition DSCG, DCC Anti-histaminic agents Illustration Text Book of Clinical Medicine - Respiratory Medicine

Features of Meptin Syrup & Tablets as A Controller Long Duration of Bronchodilating Action Anti-inflammatory Effect Our product, Procaterol, Meptin has the following features, which meet the criteria for a bronchodilator as a controller in the management of asthmatic patients, as discussed in the previous slide; 1. Long duration of bronchodilating action, 2. Anti-inflammatory effect, and 3. Reduces airway hyperreactivity. For the course of my next visits, I will be tackling individually these three functions of Procaterol. Reduces Airway Hyperreactivity

Bronchodilating Action of Procaterol Method of Administration: Intraduodenal (%) Procaterol (n=8) 0.3μg/kg Salbutamol (n=8) 3μg/kg Orciprenaline (n=4) .10μg/kg Terbutaline (n=4) 0.3μg/kg Trimetoquinol (n=4). 3μg/kg 60 Inhibition of Airway Resistance mean±S.E. 30 As you can see in this slide, Procaterol has a longer duration of bronchodilating action of more than 8 hours, which is much longer than those of salbutamol and terbutaline. 1 2 3 4 5 6 8 (hr.) Postーadministration Kawamura et al: Unpublished Data (Internal Use)

Duration of Action of Meptin Tablets 60 70 80 90 100 110 120 130 140 150 160 (%) START Meptin 0.1mg Metaproterenol 20mg Salbutamol 4mg Trimetoquinol 6mg Control FEV1.0 Meptin tablet 50 µg This slide shows another evidence demonstrating the long duration of action of our product, Procaterol, Meptin lasting up to more than 12 hours, thus proving its beneficial effect especially when given at bedtime to patients suffering from nocturnal asthma. 18 20 22 0 2 4 6 8 10 12 PM AM Yakura, T. et. al.: Gendai Iryo. 10:1499 (1978)

Results of Clinical Study with Meptin Improvement of Sleep (%) 100 n = 94 (Acute Pediatric Bronchitis) Meptin 25mcg tablets 50 Clinical results have shown that our product, Procaterol, Meptin improved sleep in almost 50% of the patients in this study on the first day of administration, and in almost 100% of them on the 3rd day. This long duration of action of our product, Procaterol, Meptin not only provides restful sleep at night to asthmatic patients, but also benefits to their parents in case of pediatric patients and other relatives tasked with taking care of them as they don’t have to wake up in the wee hours of the morning just to attend to the need of the patient undergoing an attack. 53 1 53 2 53 3 53 4 52 5 50 6 48 7 44 (Days) (n) Matsuyama et. al.: Clinical Pediatrics, 43 (2), 373 (1990)

Dosage and Administration: Meptin® Syrup The usual adult dosage is 10 ml of Meptin® Syrup (50 µg of procaterol hydrochloride) once before bed or twice (in the morning and before bed) a day by oral route. The dosage in children 6 years of age or older is 5 ml of Meptin® Syrup (25 µg of procaterol hydrochloride) once before bed or twice (in the morning and before bed) a day by the oral route. The dosage in children less than 6 years of age is 0.25 ml of Meptin® Syrup (1.25 µg of procaterol hydrochloride) per Kg body weight once before bed or twice (in the morning and before bed) a day by the oral route. The dosage may be adjusted according to the patient’s age and severity of symptoms. Meptin® Syrup The usual adult dosage is 10 ml of Meptin® Syrup (50 µg of procaterol hydrochloride) once before bed or twice (in the morning and before bed) a day by oral route. The dosage in children 6 years of age or older is 5 ml of Meptin® Syrup (25 µg of procaterol hydrochloride) once before bed or twice (in the morning and before bed) a day by the oral route. The dosage in children less than 6 years of age is 0.25 ml of Meptin® Syrup (1.25 µg of procaterol hydrochloride) per Kg body weight once before bed or twice (in the morning and before bed) a day by the oral route. The dosage may be adjusted according to the patient’s age and severity of symptoms.

Dosage and Administration: Meptin® Tablet 50 µg The usual adult dosage of Meptin® Tablet is one tablet (50 µg), orally once before bed or twice (in the morning and before bed) per day. The dosage should be adjusted according to the patient’s age and severity of symptoms. Meptin® Tablet 25 µg The usual dose of Meptin® 25 µg tablet is two tablets (50 µg) once before bed or twice (in the morning and before bed) per day by the oral route. The dosage in children 6 years of age or older is one tablet (25 µg), once before bed or twice (in the morning and before bed) per day by the oral route. The dosage should be adjusted according to the patient’s age and severity of symptoms. This slide is just a reminder of the proper dosage and administration of Meptin Tablets. Meptin® Tablet 50 µg The usual adult dosage of Meptin® Tablet is one tablet (50 µg), orally once before bed or twice (in the morning and before bed) per day. The dosage should be adjusted according to the patient’s age and severity of symptoms. Meptin® Tablet 25 µg The usual dose of Meptin® 25 µg tablet is two tablets (50 µg) once before bed or twice (in the morning and before bed) per day by the oral route. The dosage in children 6 years of age or older is one tablet (25 µg), once before bed or twice (in the morning and before bed) per day by the oral route. The dosage should be adjusted according to the patient’s age and severity of symptoms.

MEPTIN: ORAL & INHALED DURATION OF ACTION ORAL: 10 to 12 hours ONSET OF ACTION ORAL: 30 to 60 minutes INHALED: 3 to 5 minutes Meptin is available in both oral and inhaled form. The difference is in the duration and onset of action for your patients.

Thank you for your time in listening to my presentation, doctor. As you can see, here is the line up of our respiratory products. Meptin Syrup, Tablets, and Swinghaler, together with Budesonide Obucort, are all approved for the relief of asthma symptoms. Meptin has been, and ever will be the reliable choice through the years for Asthma management and control.